Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemiaZachary R. Hunter, Steven P. Treon, Xia Liu et al.|Blood Advances|2018Cited by 90
The <scp>BCL</scp>2 antagonist <scp>ABT</scp>‐199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in <i><scp>CXCR</scp>4</i><sup><i>Wild‐type</i></sup> and <i><scp>CXCR</scp>4</i><scp><sup><i>WHIM</i></sup></scp> mutated Waldenstrom macroglobulinaemia cellsYang Cao, Steven P. Treon, Guang Yang et al.|British Journal of Haematology|2015Cited by 71
SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomasManit Munshi, Guang Yang, Xia Liu et al.|Blood Cancer Journal|2020Cited by 45
<i>MYD88</i> mutated and wild-type Waldenström’s Macroglobulinemia: characterization of chromosome 6q gene losses and their mutual exclusivity with mutations in <i>CXCR4</i>Maria Luisa Guerrera, Zachary R. Hunter, Nickolas Tsakmaklis et al.|Haematologica|2018Cited by 42